"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
- Patient Information:
Clinical testing of OCUCOAT (hydroxypropylmethylcellulose) showed it to be extremely well tolerated after injection into the human eye.
A transient rise in intraocular pressure postoperatively has been reported in some cases.
Rarely, postoperative inflammatory reactions (iritis, hypopyon), as well as incidents of corneal edema and corneal decompensation, have been reported with viscoelastic agents. Their relationship to OCUCOAT (hydroxypropylmethylcellulose) has not been established.
Read the Ocucoat (hydroxypropylmethylcellulose) Side Effects Center for a complete guide to possible side effects
No Information Provided.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Ocucoat Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.